|
市場調査レポート
商品コード
1384927
モバイルECGデバイスの世界市場規模、シェア、産業動向分析レポート:モダリティ別、最終用途別、地域別展望と予測、2023年~2030年Global Mobile ECG Devices Market Size, Share & Industry Trends Analysis Report By Modality (Handheld, Band, Pen, and Others), By End-use (Hospitals & Diagnostic Centers, Ambulatory Care, and Homecare), By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
モバイルECGデバイスの世界市場規模、シェア、産業動向分析レポート:モダリティ別、最終用途別、地域別展望と予測、2023年~2030年 |
出版日: 2023年10月31日
発行: KBV Research
ページ情報: 英文 291 Pages
納期: 即納可能
![]() |
モバイルECGデバイス市場規模は、予測期間中にCAGR 12.2%で成長し、2030年には51億米ドルに達すると予測されます。2022年の市場規模は849万2,600台、成長率は17.5%(2019-2022年)となっています。
KBV Cardinalのマトリックスに示された分析によると、Medtronic PLCは市場の主要な先駆者です。GE HealthCare Technologies, Inc.、AliveCor, Inc.、Koninklijke Philips N.V.などの企業は、市場における主要なイノベーターです。2022年3月、GE HealthCare Technologies, Inc.はAliveCorとパートナーシップを締結し、AliveCor KardiaMobile 6L ECG装置で患者が撮影した医療グレードの6誘導心電図(ECG)を病院外で提供します。
COVID-19の影響
多くの患者が遠隔モニタリングを受け入れた一方で、一部の患者、特に高齢者層は、モバイルECGデバイスの導入と使用に課題を抱えていました。技術的な障壁や装置の精度やセキュリティに対する懸念が、使用をためらわせる原因となっています。このことは、今後のモバイルECG機器におけるユーザーフレンドリーで利用しやすい設計の重要性を浮き彫りにしました。さらに、パンデミックは遠隔医療と遠隔患者モニタリングの採用を加速させました。患者やヘルスケアプロバイダーは、特に感染率の高い地域で、直接の接触を減らすために遠隔医療ソリューションにますます注目するようになっています。モバイルECGデバイスはこのシフトにおいて極めて重要な役割を果たし、患者が遠隔で心臓の健康状態をモニターできるようにしました。このような遠隔医療の急増は、モバイルECG機器の需要を増加させただけでなく、特に心臓疾患を持つ患者に継続的なケアを提供する上での重要性を浮き彫りにしました。
市場成長要因
心血管疾患の有病率の増加
世界の人口が高齢化し、ライフスタイルに関連する危険因子が増加し続ける中、心血管疾患の有病率は増加すると予想されます。世界保健機関(WHO)によると、心血管疾患(CVD)は世界の主要死因であり、年間約1,790万人の命に影響を及ぼしています。心臓発作と脳卒中は、CVDに関連する死亡者数の5人に4人以上を引き起こし、これらの早期死亡の3分の1は70歳未満で発生しています。これらの機器は、ユーザーが健康管理に積極的に関与できるようにし、健康への積極的なアプローチを促進します。また、予防ヘルスケアをより重視し、治療から早期発見とリスク軽減に重点を移すことを促しています。そのため、心血管疾患の流行は市場に重要かつプラスの影響を及ぼしています。
ホリスティック・ヘルス・モニタリングとウェアラブル統合の提供
ホリスティック・ヘルス・モニタリングには、心臓の健康だけでなく、個人の幸福のさまざまな側面の追跡が含まれます。このアプローチは、より患者中心で予防的なモデルへのヘルスケアにおける広範なシフトと一致します。活動追跡、睡眠分析、ストレス管理などのホリスティック・ヘルス・モニタリング機能とモバイルECGデバイスを統合することで、個人の全体的な健康状態を総合的に把握することができます。ウェアラブル統合のもう一つの大きな利点は、ヘルスケアプロバイダーにとってECGデータの可視性が高まることです。ECGデータが患者のウェアラブル端末に直接送信されることで、患者の遠隔モニタリングがより効果的になります。こうした動向は今後も進化を続け、市場の成長をさらに促進すると予想されます。
市場抑制要因
データプライバシーとセキュリティへの懸念
データのプライバシーとセキュリティに関する懸念がもたらす主な悪影響の1つは、ユーザーからの信頼の欠如です。モバイルECG機器を使用する患者や個人は、当然のことながら、機密性の高い健康データの安全性について不安を抱いています。不正アクセス、データ漏洩、または個人健康情報の悪用に対する恐怖は、潜在的な利点があるにもかかわらず、これらの機器の採用を躊躇させる可能性があります。データの安全性に対する懸念から、ヘルスケア専門家は患者が収集したECGデータの使用に慎重になり、遠隔患者モニタリングや遠隔医療サービスの価値が制限される可能性があります。このような消極的な姿勢は、ヘルスケア・ワークフローへのモバイルECG機器のシームレスな導入を妨げる可能性があります。したがって、ECG機器に関連する重大なデータプライバシーとセキュリティの問題は、市場の成長を妨げる可能性があります。
モダリティの展望
モダリティに基づき、市場はペン型、バンド型、ハンドヘルド型、その他に分けられます。2022年の市場では、バンド型セグメントがかなりの成長率を確保しました。バンド型モバイルECGデバイスは、ユーザーの心臓リズムを継続的にモニタリングできます。デバイスは腕時計のようにバンドまたは手首に装着され、長時間(通常は24時間)継続的にECGデータを記録します。これらの装置は、不整脈が検出された場合に即座に警告や通知を送るようにプログラムすることができます。これは、心房細動やその他の不整脈のような疾患のある人にとっては、タイムリーな医療介入を促すことができるため、救命のための機能となりうる。このような利点により、バンド型ECG機器は、継続的な心臓モニタリングと予防的な心臓の健康管理を必要とする個人にとって価値あるツールとなります。
最終用途の展望
最終用途別に見ると、市場は病院・診断センター、外来医療、在宅医療に分けられます。在宅ケア分野は2022年に市場で大きな収益シェアを記録しました。この拡大は、家庭での医療に手頃な価格と使いやすさに起因しています。在宅ヘルスケア機器の需要は、技術の進歩やヘルスケア製品の小型化によって、より利用しやすく使いやすくなったことが背景にあります。さらに、モバイルECG機器の採用は、対象人口の増加、医療費抑制ニーズの高まり、これらの機器が対象とする疾患の多さなどの要因によって大きく後押しされると予想されます。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。北米セグメントは、2022年の同市場における収益シェアが最大となっています。この地域の市場は、老人人口の多さ、洗練されたヘルスケアインフラ、比較的高い可処分所得など、多くの要因によって大きく成長すると予想されます。在宅ヘルスケアを支援する政府のプログラムや医療費の削減は、市場拡大の主な要因になると予想されます。
The Global Mobile ECG Devices Market size is expected to reach $5.1 billion by 2030, rising at a market growth of 12.2% CAGR during the forecast period. In the year 2022, the market attained a volume of 8,492.6 thousand units, experiencing a growth of 17.5% (2019-2022).
The need for home healthcare products and services is growing in Asia Pacific due to a number of factors, including chronic diseases requiring long-term care, costly in-hospital healthcare facilities, and an underdeveloped healthcare infrastructure. Thus, the Asia Pacific region generated $437.9 million revenue in the market in 2022. Among the developing nations in this region are South Korea, Thailand, Australia, and New Zealand. The aging population, the increasing prevalence of lifestyle diseases, including diabetes and obesity, and technological advancements in patient monitoring devices are all envisioned to drive market growth.
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In November, 2022, OMRON Healthcare, Co., Ltd. partnered with CardioSignal to create digital health solutions that would optimize workflow processes for lifestyle chronic diseases, mainly for cardiovascular disease detection at primary care, utilizing the company's motion sensor and ECG technologies. In addition, In August, 2022, Medtronic plc partnered with BioIntelliSense to allow the Medtronic Patient Monitoring business to provide access to a medical-grade device that would offer continuous vital sign measurements of general care patients in-hospital as well as post-discharge.
Based on the Analysis presented in the KBV Cardinal matrix; Medtronic PLC is the major forerunner in the Market. Companies such as GE HealthCare Technologies, Inc., AliveCor, Inc. and Koninklijke Philips N.V. are some of the key innovators in the Market. In March, 2022, GE HealthCare Technologies, Inc. entered into a partnership with AliveCor to provide medical-grade six-lead electrocardiograms (ECGs) taken by patients on an AliveCor KardiaMobile 6L ECG device outside of the hospital setting.
COVID-19 Impact
While many patients embraced remote monitoring, some individuals, especially older populations, faced challenges in adopting and using mobile ECG devices. Technological barriers and concerns about device accuracy or security led to hesitancy. This underscored the importance of user-friendly and accessible design in future mobile ECG devices. Moreover, the pandemic accelerated the adoption of telehealth and remote patient monitoring. Patients and healthcare providers increasingly turned to telemedicine solutions to reduce in-person contact, especially in areas with high infection rates. Mobile ECG devices played a pivotal role in this shift, allowing patients to monitor their cardiac health remotely. This surge in telehealth not only increased the demand for mobile ECG devices but also highlighted their importance in providing continuous care to patients, particularly those with heart conditions.
Market Growth Factors
Increasing prevalence of cardiovascular diseases
As the global population ages and lifestyle-related risk factors continue to rise, the prevalence of cardiovascular conditions is expected to increase. According to the World Health Organisation (WHO), cardiovascular diseases (CVDs) are the primary cause of death globally, affecting approximately 17.9 million lives annually. Heart attacks and strokes cause more than four out of five CVD-related fatalities, and one-third of these premature deaths occur in individuals under 70. These devices empower users to actively engage in their health management, fostering a proactive approach to their well-being. It has also encouraged a greater emphasis on preventive healthcare, shifting the focus from treatment to early detection and risk reduction. Therefore, the prevalence of cardiovascular diseases exerts a significant and positive impact on the market.
Provision of holistic health monitoring and wearable integration
Holistic health monitoring involves the tracking of various aspects of an individual's well-being beyond just heart health. This approach aligns with the broader shift in healthcare toward a more patient-centered and preventive model. The integration of mobile ECG devices with holistic health monitoring features, such as activity tracking, sleep analysis, and stress management, creates a holistic picture of an individual's overall health. Another significant benefit of wearable integration is that it enhances the visibility of ECG data for healthcare providers. Remote patient monitoring is made more effective when ECG data is transmitted directly to a patient's wearable device. As these trends continue to evolve, they are expected to further drive the growth of the market.
Market Restraining Factors
Data privacy and security concerns
One of the primary negative impacts of data privacy and security concerns is a lack of user trust. Patients and individuals who use mobile ECG devices are understandably apprehensive about the safety of their sensitive health data. The fear of unauthorized access, data breaches, or misuse of personal health information can deter individuals from adopting these devices despite their potential benefits. Concerns about data security may lead to healthcare professionals being cautious about using ECG data collected by patients, which can limit the value of remote patient monitoring and telehealth services. This reluctance can impede the seamless adoption of mobile ECG devices into healthcare workflows. Therefore, the significant data privacy and security issues associated with ECG devices may hamper the growth of the market.
Modality Outlook
Based on modality, the market is divided into pen, band, handheld, and others. The band segment procured a considerable growth rate in the market in 2022. Band-style mobile ECG Devices allow for continuous monitoring of the user's heart rhythm. The device is worn as a band or on the wrist, similar to a watch, and it records ECG data continuously for a long time-usually around the clock. These devices can be programmed to send immediate alerts or notifications if irregular heart rhythms are detected. This can be a lifesaving feature for individuals with conditions like atrial fibrillation or other arrhythmias, as it can prompt timely medical intervention. These benefits make band-style ECG devices a valuable tool for individuals who require continuous cardiac monitoring and proactive heart health management.
End-use Outlook
On the basis of end-use, the market is divided into hospitals & diagnostic centers, ambulatory care, and homecare. The homecare segment recorded a significant revenue share in the market in 2022. This expansion is ascribed to its affordability and ease of use for at-home medical care. The demand for home healthcare devices is driven by technological advancements as well as the miniaturization of healthcare products, which make them more accessible and user-friendly. Furthermore, the adoption of mobile ECG devices is anticipated to be significantly aided by factors like a growing target population, an increasing need to control healthcare costs, and a significant number of diseases targeted by these devices.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment witnessed the maximum revenue share in the market in 2022. This region's market is expected to grow significantly due to a number of factors, including a large geriatric population, sophisticated healthcare infrastructure, and comparatively high disposable incomes. Government programs to support home healthcare and lower healthcare costs are anticipated to be major factors in the market's expansion.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group), Nihon Kohden Corporation, GE HealthCare Technologies, Inc., Medtronic PLC, iRhythm Technologies, Inc., Koninklijke Philips N.V., OMRON Corporation, Nureca Limited (Dr Trust), EMAY, and AliveCor, Inc.
Recent Strategies Deployed in Mobile ECG Devices Market
Partnerships, Collaborations & Agreements
Oct-2023: GE HealthCare Technologies, Inc. partnered with AliveCor, a medical device and AI company. Through this partnership electrocardiogram readings taken on the medical device company's personal EKG device would be delivered directly into GE Healthcare's MUSE Cardiac Management System.
Aug-2023: AliveCor, Inc. collaborated with Clario, a healthcare research technology company. This collaboration aimed to allow trial participants to collect medical-grade six-lead ECG readings in the comfort of their own homes through KardiaRx, a clinical-trial-focused app.
Jun-2023: AliveCor, Inc. came into partnership with Vieroots Wellness Solutions, a health-tech start-up dedicated to offering personalized solutions to improve health and longevity. This partnership aimed to bring together the power of two innovative companies, allowing them to provide digital health products and services to consumers.
Jun-2023: AliveCor, Inc. came into collaboration with Luscii, Europe's market leader in remote patient monitoring and virtual ward providers. This collaboration aimed to launch the world's first 'virtual heart clinic in a box', revolutionizing cardiac care for millions of patients by making it easy for any hospital or GP to provide high-quality, remote patient monitoring to their patients.
Nov-2022: OMRON Healthcare, Co., Ltd. partnered with CardioSignal, a health technology company. This partnership aimed to create digital health solutions that would optimize workflow processes for lifestyle chronic diseases, mainly for cardiovascular disease detection at primary care, utilizing the company's motion sensor and ECG technologies.
Sep-2022: AliveCor, Inc. came into partnership with BIOTRONIK, a privately owned, global medical device company. This partnership aimed to combine the power of BIOTRONIK's BIOMONITOR Injectable Cardiac Monitor with AliveCor's AI-enabled, clinically validated, medical-grade KardiaMobile 6L and KardiaMobile Card ECG technology.
Aug-2022: Medtronic plc partnered with BioIntelliSense, a continuous health monitoring and clinical intelligence company. This partnership aimed to allow the Medtronic Patient Monitoring business to provide access to a medical-grade device that would offer continuous vital sign measurements of general care patients in-hospital as well as post-discharge.
Aug-2022: AliveCor, Inc. partnered with Dignio, a leading specialist in remote care. This partnership aimed to allow seamless transmission of electrocardiograms (ECG) recorded by patients in the community directly to clinicians.
Apr-2022: GE HealthCare Technologies, Inc. collaborated with Medtronic plc, an American medical device company. Following this collaboration, customers could access extensive product offerings, financial solutions, and exceptional service.
Mar-2022: GE HealthCare Technologies, Inc. entered into a partnership with AliveCor, a medical device and AI company that develops ECG hardware and software compatible with consumer mobile devices. This partnership aimed to provide medical-grade six-lead electrocardiograms (ECGs) taken by patients on an AliveCor KardiaMobile 6L ECG device outside of the hospital setting.
Sep-2021: Medtronic plc came into partnership with Statis Health, a unit of Stasis Labs. This partnership aimed to promote the latter's bedside patient monitoring system in India.
Apr-2020: AliveCor, Inc. partnered with Omron Healthcare, the world's leading medical device company. This partnership aimed to integrate AliveCor's mobile device ECG technology with blood pressure devices from Omron to better serve clients and widen access to remote patient care.
Mergers & Acquisition
Nov-2021: Royal Philips took over Cardiologs, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. This acquisition aimed to empower Philips' cardiac monitoring and diagnostics portfolios with innovative software technology, electrocardiogram (ECG) analysis, and reporting services.
Feb-2021: Royal Philips acquired BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. This acquisition aimed to strongly fit with Philips' cardiac care offerings, and its strategy to transform the delivery of care along the health continuum with integrated solutions.
Product Launches and Product Expansions
Aug-2023: GE HealthCare Technologies, Inc. rolled out CardioVisio for Atrial Fibrillation (AFib), a digital tool. The launched product would be created to assist clinicians in visualizing longitudinal data relevant to disease progression from multiple data sources.
May-2022: AliveCor, Inc. released KardiaComplete, a comprehensive heart health enterprise solution. The launched product would be created to drive improved health outcomes and reduce the cost of cardiac care.
Feb-2022: AliveCor, Inc. launched KardiaMobile Card, a new credit-card-size personal ECG. The launched product would be capable of taking a single-lead ECG in 30 seconds.
Jan-2022: Royal Philips introduced a 12-lead electrocardiogram (ECG) solution, the industry's first full-service, at-home. The launched product would be patient-centric ECG portfolios within the company's cardiac monitoring offerings, pairing data readings comparable to clinical, site-based ECGs with Philips' leading cloud-based data collection and analysis services.
Nov-2021: GE HealthCare Technologies, Inc. announced the launch of around 60 innovative technology solutions spanning the healthcare spectrum consisting of patient screening, diagnostics, therapy planning, guidance, and monitoring. The launched product would be utilized to Solve Healthcare's Most Pressing Problems.
Jul-2021: OMRON Corporation rolled out OMRON Complete, the first single-lead electrocardiogram (ECG) and blood pressure monitor for home use. The launched product would be created for the detection of atrial fibrillation (AFib), the most frequently encountered arrhythmia in clinical practice.
Jan-2020: Nihon Kohden Corporation unveiled the Life Scope SVM-7200 Series vital signs monitor, a monitor designed for outpatient facilities and beds that traditionally are not continuously monitored. The launched product would enable healthcare practitioners to quickly and easily measure three vital signs which include blood oxygen, blood pressure, and temperature.
Approvals
Oct-2022: Medtronic plc got FDA approval for conduction system pacing, which would expand the flexibility of its pacemaker hardware. The approved product would connect the implant's leads directly to the bundles of intertwined cells that would help govern the repeated contractions of the cardiac muscle.
Jul-2022: iRhythm Technologies, Inc. got FDA approval for FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) System. The approved product would work with a wearable to monitor patients with atrial fibrillation and irregular heart rhythm.
Market Segments covered in the Report:
By Modality (Volume, Thousand Units, USD Billion, 2019-2030)
By End-use (Volume, Thousand Units, USD Billion, 2019-2030)
By Geography (Volume, Thousand Units, USD Billion, 2019-2030)
Companies Profiled
Unique Offerings from KBV Research